Comment on CMS-2026-1256-0002
Becton, Dickinson and Company (BD)OpposeAdvocacy
Summary: BD (Becton, Dickinson and Company) opposes the proposed repeal of the alternative NTAP and OPPS device pass-through pathways, arguing that it creates a misalignment between FDA regulatory frameworks and CMS payment criteria. The company contends that the repeal imposes duplicative evidentiary requirements on breakthrough technologies, potentially delaying market entry and reducing investment in medical innovation.
On behalf of BD (Becton, Dickinson and Company), I am pleased to submit comments on the FY 2027 Medicare Hospital IPPS proposed rule, published April 10, 2026. We appreciate the Agency’s focus on improving outcomes, efficiency, safety, and access, and offer comments on areas relevant to the adoption of medical technology